Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (171-180 of 471) with videos related to

Pageof 48
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 6, 2021
Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fractionStefano Coiro, Nicolas Girerd, John J V McMurray, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.
Journal of the American College of Cardiology|August 20, 2011
Influence of global region on outcomes in heart failure β-blocker trialsChristopher M O'Connor, Mona Fiuzat, Karl Swedberg, et al.
Circulation. Heart Failure|June 15, 2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialAkshay S Desai, Scott Solomon, Brian Claggett, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
Journal of Cardiac Failure|January 29, 2016
Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF)Michael Fu, Jingmin Zhou, Erik Thunström, et al.
ESC Heart Failure|July 10, 2023
Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)Amr Abdin, Michel Komajda, Jeffrey S Borer, et al.
European Heart Journal|June 22, 2015
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trialNicolas Girerd, Tim Collier, Stuart Pocock, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
The New England Journal of Medicine|November 16, 2010
Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad, John J V McMurray, Henry Krum, et al.
Pageof 48

Showing results (171-180 of 471) with videos related to

Sort By:
Pageof 48
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 6, 2021
Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fractionStefano Coiro, Nicolas Girerd, John J V McMurray, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.
Journal of the American College of Cardiology|August 20, 2011
Influence of global region on outcomes in heart failure β-blocker trialsChristopher M O'Connor, Mona Fiuzat, Karl Swedberg, et al.
Circulation. Heart Failure|June 15, 2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialAkshay S Desai, Scott Solomon, Brian Claggett, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
Journal of Cardiac Failure|January 29, 2016
Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF)Michael Fu, Jingmin Zhou, Erik Thunström, et al.
ESC Heart Failure|July 10, 2023
Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)Amr Abdin, Michel Komajda, Jeffrey S Borer, et al.
European Heart Journal|June 22, 2015
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trialNicolas Girerd, Tim Collier, Stuart Pocock, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
The New England Journal of Medicine|November 16, 2010
Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad, John J V McMurray, Henry Krum, et al.
Pageof 48